Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset

Documenti analoghi

• Sex differences in patterns of chronic kidney disease care in Australian primary care: A retrospective cohort study of a national general practice dataset
  di: Hannah Wallace, et al.
  Pubblicazione: (2026)
• Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data
  di: Daniel Bekele Ketema, et al.
  Pubblicazione: (2025)
• Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial
  di: Ying Zhu, et al.
  Pubblicazione: (2025)
• Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
  di: Juliana de Oliveira Costa, et al.
  Pubblicazione: (2024)
• Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
  di: Tamara Y. Milder, et al.
  Pubblicazione: (2024)